Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora.
A multiple-dose, randomized, double-blind, controlled, cross-over trial was performed in 12 healthy male subjects in order to investigate the effect of a 7-day treatment with moxifloxacin (400 mg orally, once daily) versus clarithromycin (500 mg orally, twice daily) on the normal oropharyngeal microflora. Moxifloxacin caused significant reductions in levels of alpha-streptococci and Neisseria cocci during the treatment period, while the numbers of gram-negative anaerobic bacteria increased markedly during moxifloxacin administration. Clarithromycin administration caused a suppression of micrococci and corynebacteria, while no significant changes were recorded in the anaerobic microflora. No new colonizing moxifloxacin-resistant strains were isolated during the investigation period.
Beyer
G
G
Pneumologie und Infektiologie, Hospital Heckeshorn, Freie Universität Berlin, Germany.
Hiemer-Bau
M
M
Ziege
S
S
Edlund
C
C
Lode
H
H
Nord
C E
CE
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002175:Candida / Q000187:drug effects; D017291:Clarithromycin / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D009343:Neisseria / Q000187:drug effects; D009960:Oropharynx / Q000382:microbiology*; D018720:Prevotella / Q000187:drug effects; D011804:Quinolines; D013291:Streptococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D017291:Clarithromycin; D000077266:Moxifloxacin